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Summary A standard dose of Adriamycin (60 mgm-2) was administered to 30 patients with inoperable
hepatocellular carcinoma, 16 of whom were hyperbilirubinaemic (18-37 tLmol-1). The hyperbilirubinaemic
patients experienced marked myelosuppression, but only minor symptomatic side-effects. The degree of
neutropenia was directly related to the serum bilirubin concentration, but not to any other standard liver test,
presence or absence of cirrhosis, or any pharmacokinetic parameter studied including the area under the
Adriamycin or adriamycinol concentration-time curve to 48 h or infinity, or the terminal half-life of
Adriamycin. The area under the log concentration-time curve was significantly greater for both Adriamycin
and adriamycinol in patients who were hyperbilirubinaemic compared to those with normal bilirubin. Whilst
hyperbilirubinaemic patients may tolerate a full dose of Adriamycin, we found no evidence that this was
associated with a better response rate, which was disappointingly low at only 18%.
Adriamycin (doxorubicin) remains the most effective single
agent in the chemotherapy of inoperable hepatocellular carc-
inoma (HCC) although the response rate is no more than
30% (Olweny et al., 1975; Vogel et al., 1977; Johnson et al.,
1978). We have previously undertaken a detailed statistical
analysis to determine which clinical and biochemical features
were independently associated with subsequent response to
Adriamycin. This analysis, based on data from 143 patients
treated at a single centre showed a normal serum bilirubin
level to be the only factor which correlated with an increased
likelihood of response (Johnson et al., 1986). These findings
can be interpreted as showing that hyperilirubinaemia (or
some factor closely associated with it) was either a genuine
adverse factor affecting the response to Adriamycin, or that
the response rate was lower in hyperbilirubinaemic patients
because of the dose reduction recommended. The recom-
mended dose adjustments were based on experience in hyper-
bilirubinaemic patients with secondary liver cancer who
developed severe myelosuppression and mucositis when given
standard, unadjusted regimens (Benjamin et al., 1981). Such
guide lines may not be appropriate in patients with primary
liver cancer in whom there may be less destruction of func-
tioning liver tissue by the tumour (Chan et al., 1980;
Chlebowski et al., 1980).
The aim of this present study was, therefore, to determine
how patients with HCC and moderate hyperbilirubinaemia
tolerate a standard 60mgm-2 dose of Adriamycin and to
assess the clinical efficacy of this regimen. In addition, we
have investigated the extent to which the serum bilirubin
concentration and other standard liver tests predict treatment
toxicity, and correlated both these with measured pharma-
cokinetic parameters of drug clearance and metabolism.
Patients and Methods
Thirty consecutive patients with a Karnofsky Score ofgreater
than 50%, and serum bilirubin levels below 40jsmol 1', were
studied between March 1987 and March 1989. In 16 levels
were above the limit of the reference range for our laboratory
(17gmol-') at presentation. Twenty-eight of the patients
fulfilled our standard criteria for the diagnosis of hepatocel-
lular carcinoma: either a serum alpha-fetoprotein (AFP) level
of greater than 500 ng ml-' in a patient known to have
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cirrhosis with an hepatic mass demonstrated on either ult-
rasonography or CT scanning, or diagnostic histology. In
addition, two patients, both women, had liver tumours which
were considered histologically to be compatible with, but not
diagnostic of, HCC. Neither had any evidence of an ext-
rahepatic primary lesion. One patient had an AFP level of
120ngml-' rising to 250ngml-', and one was hypercal-
caemic with histological appearances of a scirrhous tumour
previously described by Peters as a variant of HCC (Peters,
1976). The laboratory and clinical features of the 30 patients,
all of whom had disease which was too extensive for surgical
resection, are given in Table I.
Starting in January 1986 a record was kept of the serum
bilirubin levels of 100 consecutive patients with HCC seen on
the Institute (i.e. including those declining to enter, or not
meeting entry criteria for this study, or undergoing surgical
treatment) to determine the extent to which the group under
study was representative of the total patient population.
Liver tests {aspartate aminotransferase (AST), alkaline
phosphatase (ALP), serum albumin and bilirubin} were
measured on the morning of treatment. Hyperbilirubinaemia
was defined as a serum bilirubin level exceeding 17jLmol 1-',
the upper limit of the reference range for our laboratory.
Adriamycin was administered intravenously as a bolus injec-
tion at a dose of 60 mg per square metre of estimated body
surface area. Toxicity and side-effects including the frequency
and severity of nausea and vomiting were recorded. A full
blood count, including haemoglobin concentration, total
white cell count (WCC) and platelet count, was taken
immediately prior to Adriamycin administration, and subse-
quently, wherever possible, on days 7, 14 and 21.
Bloodsampling and drug analysis
Whole venous blood samples (7 ml) were taken into lithium
heparin tubes prior to and at 5, 10, 20, 30, 40 min, 1, 2, 3, 6,
12, 20, 24, 30, 48 and, where possible, 72 h following injec-
tion of the drug. Plasma was separated immediately and
stored at -20'C pending analysis. Plasma Adriamycin and
adriamycinol concentrations were measured by a high per-
formance liquid chromatography (HPLC) technique with
fluorometric detection (Dobbs & James, 1987). Briefly, this
involved extraction of Adriamycin and adriamycinol from
plasma samples onto cartridges containing a C2 bonded-silica
material. Loaded cartridges were then introduced into the
solvent stream of an HPLC system by an advanced
automated sample processor (ASAP R; Varia Associated,
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Walton-upon-Thames, UK). Peak heights were measured by
a computing integrator and used to calculate peak height
ratios for drug and metabolite. The detection limit for this
method is 2 ng ml-'. The necessary level of containment
could not be provided for the safe extraction of samples
obtained from patients known to be positive for the hepatitis
B surface antigen (HBsAg) using this technique. Such sam-
ples were extracted by a chloroform:2-propanol (1:1) mixture
as described by Andrews, Brenner, and Chou et al. (1984).
Following evaporation of this solvent virological analysis
indicated that these extracts could be handled safely. Ext-
racted residues were redissolved in 150 gll of solvent and 50
injected into the HPLC system manually (detection limit
4-5 ng ml-'). All other conditions for the assay were the
same as for the former method.
Pharmacokinetic analysis
Plasma drug concentration-time data were fitted to both two
and three compartment models using an iterative least
squares regression programme with weighted, 1 y-2 data
(Yamaoka et al., 1981; Johnston & Woollard, 1983).
Minimisation of the residual sum of squares and Akaike's
information criteria (Yamaoka et al., 1978) were used to
define the best choice of model to fit the data. The area
under the plasma drug concentration-time curve (AUC) to
48 h was measured using the linear trapezoidal approxima-
tion for both Adriamycin and adriamycinol together with the
AUC extrapolated to infinity, and the terminal half-life of
Adriamycin.
Assessment of response
Response was assessed 2 to 3 weeks after the first injection of
Adriamycin and then at 6-weekly intervals according to
WHO guidelines (WHO handbook, 1979). A response was
considered to have occurred when there was at least a 30%
reduction in hepatomegaly as assessed clinically by distance
below the costal margin or at least a 50% reduction in
tumour diameter on serial ultrasound examination in patients
with a solitary mass. In addition, a response was recorded if
there was at least a 50% fall in the serum AFP level (where
the pretreatment levels was greater than 250 ngml-') pro-
vided that there was no contradictory evidence from the
other two criteria.
Statistical approach
To assess the impact of the liver tests and pharmacokinetic
parameters on the degree of myelosuppression we undertook
an initial series of univariate analyses, followed by stepwise
multiple regression analysis (BMDP: University of Califor-
nia, 1981). The independent influence of each of the liver
tests, the AUC curve to 48 h (for Adriamycin and
adriamycinol) and extended to infinity (Adriamycin only),
and the terminal half-life (Adriamycin only) on the nadir
values for haemoglobin, WCC and platelet count was
examined. In all instances the white cell nadir was on day 14.
The distributions of values of alkaline phosphatase, AST and
platelet count were highly skewed, and the analysis was
therefore undertaken after logarithmic transformation of this
data. Differences in cumulative time-concentration curves
were compared by applying Student's t-test at each individual
time point, and patient survival curves were calculated using
the Kaplan-Meier method.
The investigation protocol was passed by the Ethical Com-
mittee of King's College Hospital and all patients gave in-
formed consent after being appraised of the possible risks
involved.
Results
Of the 16 hyperbilirubinaemic patients studied, five were
unevaluable for response (one died within one week of star-
ting treatment, and four overseas patients returned home
where they could not be further traced). A response was
documented in two patients. One of these died suddenly, 3
Table I Pre-treatment clinical and laboratory features of the 30 patients studied
Age AST SAP ALB Bilirubin Hb WCC Platelets
Patient (years) Sex Nationality Cirrhosis (IUI-') (IUIt') (g1') (pmol1') (g1') ( x 1091') ( x 1091-') HBsAg
1 56 M UK CAH 34 114 37 36 13.4 2.2 62 -
2 67 M UK ALD 115 440 36 20 10.1 7.4 226 -
3 30 M India NK 66 143 41 15 13.5 8.7 213 -
4 50 F Saudi Arabia NK 47 183 29 34 12.8 7.9 152 -
5 72 M UK CAH 95 244 34 12 10.3 3.9 188 +
6 52 M Portugal CRY 101 163 35 37 12.5 6.6 94
7 71 F UK NK 145 393 32 22 10.8 6.8 499 -
8 76 M UK CRY 110 155 32 29 17.7 8.2 162 -
9 75 M Saudi Arabia CRY 180 393 22 25 9.8 6.1 280 -
10 24 M Ghana CAH 321 957 34 29 11.6 5.7 323 -
11 42 M Cambodia CAH 31 119 37 9 15.8 6.7 158 +
12 55 M Djibouti CAH 49 464 33 34 12.1 3.5 97 -
13 58 M UK CRY 56 277 31 17 10.5 15.8 327 -
14 33 F UK 39 400 29 13 11.7 16.4 227 -
15 47 F Philippines NK 34 140 38 12 14.1 10.3 341 -
16 36 F UK 73 348 41 5 13.5 11.6 368 -
17 74 M UK ALD 47 160 31 23 13.0 8.0 168 -
18 56 M Burma CRY 64 116 43 15 13.0 10.8 284
19 49 M Italy CRY 57 290 40 13 15.3 5.3
20 54 M India CAH 119 243 39 9 15.6 6.4 283 -
21 49 M Sicily CRY 103 192 27 19 11.6 6.3 119 -
22 31 F UK 41 527 38 12 16.5 11.1 246 -
23 69 M UK NK 59 213 35 13 9.1 4.4 246 -
24 60 M UK ALD 64 272 29 31 12.5 5.0 100 -
25 20 F UK - 119 312 33 14 9.7 6.9 439 -
26 69 F UK CAH 149 648 31 28 9.5 8.1 425 -
27 43 F Kuwait 136 335 36 9 10.0 3.9 79 -
28 51 F Ghana NK 156 975 25 20 9.5 12.0 66 +
29 52 M Hong Kong NK 57 228 30 37 14.2 3.3 105 +
30 63 M Egypt ALD 284 178 24 32 10.1 4.2 202
CAH = chronic activehepatitis, ALD = alcoholic liverdisease, CRY = cryptogenic, NK = not known, SAP = serum alkalinephosphatase,
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Figure 1 Comparison of terminal half life and area under the
concentration-time curves (at 48 h), for Adriamycin and adria-
mycinol in relation to hyperbilirubinaemia. The mean values are
greater for each parameter in the hyperbilirubinaemic patients
and this achieves statistical significance (P<0.01) for Adriamycin
and adriamycinol using Students t-test, but just fails to reach
statistical significance if the data is logarithmically transformed.
months after starting treatment, following a variceal hemorr-
hage related to the underlying cirrhosis. Two further patients
completed a full course of Adriamycin (total
dose = 550 mg m2) and there was no evidence of tumour
progression at 12 months. The remaining seven patients
showed tumour progression as documented radiologically
and/or by serial AFP estimations.
Three patients with a normal serum bilirubin concentration
were unevaluable (one underwent liver transplantation at 3
weeks and two were lost to follow-up overseas). One of the
11 evaluable patients with a normal bilirubin, underwent a
response, and three remain well at 6 months with no tumour
progression and seven had progressive disease. Median sur-
vival time (from diagnosis) for those with hyperbilirubin-
aemia was 4 months (range 1 to 19 months), and for those
with normal bilirubin 4 months (range 1 to 11 months).
There was no significant difference in the Kaplan-Meier sur-
vival curves for the two groups.
Pharmacokinetics
In 22 of the 30 patients a complete pharmacokinetic study
was undertaken, and in four of these this was repeated
during the second course. The remainder either declined to
enter this part of the study, could not remain in hospital for
the required period of time, or could not have an adequate
venous access established. In all instances, the Adriamycin
drug-concentration time curve was fitted best by a three
compartment model. The AUC curve to 48 h and to infinity
was significantly greater in hyperbilirubinaemic patients for
both Adriamycin and adriamycinol (Figure 1), than in those
with a normal serum bilirubin concentration. When drug
concentration time curves were calculated by taking the mean
(log) drug-concentration at each time point, the curve was
significantly higher in the hyperbilirubinaemic patients
(Figures 2a and b).
The terminal half-life of Adriamycin ranged from 11-75 h
and was not related to serum bilirubin level or any other of
the standard liver tests.
Toxicity
For the series as a whole, the nadir for the haemoglobin and
the white cell count (WCC) was consistently on day 14 and
for platelets on day 7, although the fall in white cell count
was far more profound than either of the other two (Figure
3). Despite this the white cell count had risen to more than
3 x I09 [' in all but four of the 21 patients in whom it could
be measured by day 21, and in one of these the count had
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Figure 2 Comparison of (a) log Adriamycin concentration-time
curves (ng ml-' h-') for patients with serum bilirubin concentra-
tion above (0) and below (0) 17iLmol 1' and (b) log
adriamycinol concentration-time curves for patients with serum
bilirubin levels above (0) and below 17timol I` (0). Results are
presented as mean plus or minus one standard deviation,
* = P<0.01, ** = P<0.001.
been 2.2 x I091' at the time of treatment. There was a
significant linear correlation between serum bilirubin level
and white cell count at days 7 (r = -0.6, P<0.01) and 14
(r = -0.603, P<0.01) (Figure 4), and the white cell count
was significantly lower in the hyperbilirubinaemic patients on
both days 7 and 14. No correlation was detected with any
other liver test or pharmacokinetic parameter on day 7 and
14, either using univariate or multivariate analysis.
The degree of thrombocytopenia also correlated with
serum bilirubin before logarithmic transformation of the
platelet count but when the latter was normalised, the only
Time (Days)
Figure 3 Changes in haemoglobin concentration, white cell and
platelet counts with time following the standard bolus dose of
60 mgm2 of Adriamycin given intravenously.
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Figure 4 Relation of white cell nadir (day 14) to serum bilirubin
concentration.
positive correlation was with log of serum alkaline phos-
phatase (r = 0.65, P<0.01). A single patient (Patient record
4, Table I) developed septicaemia whilst neutropenic
(WCC = 0.6 x 109, day 10) but this responded rapidly to
appropriate antibiotic therapy. Otherwise side-effects were
remarkably uncommon. All patients developed some degree
of alopecia. One patient developed severe, and one mild
mucositis. Three had rigors, lasting less than one hour, at 2,
4 and 10 h after the injection. Seven patients complained of
nausea on the morning following drug administration and
this was associated with vomiting in four.
Of the 100 consecutive patients with HCC surveyed since
1986, the serum bilirubin was above 40ftmol 1' in 29%,
between 18 and 39 ,.mol l-' in 39% and within the reference
range in 39%.
Discussion
More than 60% of our patients with HCC were hyper-
bilirubinaemic at presentation and would, therefore, be can-
didates for Adriamycin dosage reduction using conventional
regimens. Although we show here that it may be safe to
administer a full dose of Adriamycin to those HCC patients
with mild hyperbilirubinaemia, the number of evaluable
patients was too small for us to make a confident statement
as to whether this regimen might influence response or sur-
vival rate.
Nonetheless, the response rate of only 18% was disappoint
ingly low and similar to the figure obtained in a previous
study of patients in whom the Adriamycin dose was
decreased in line with the degree of hyperbilirubinaemia
(Johnson et al., 1986).
In our previous study (Johnson et al., 1986) the response
rate was higher (45%) in those with normal bilirubin levels
suggesting that hyperbilirubinaemia (or a factor closely
associated with it) is a genuine adverse factor indicating a
decreased likelihood of response to Adriamycin and that the
overall response rate, in a particular group of patients, will
be related to the distribution of bilirubin levels. This observ-
ation was not confirmed in the present study although the
number of patients in the trial is considerably smaller, and
this reflects the trend that response rates quoted in more
recent studies are lower than the initial reports. It is difficult
to compare survival figures with early series since these are
influenced to a considerable extent by the time of diagnosis
of the tumour, and with the advent of screening programmes
for patients with cirrhosis and much more sensitive ultra-
sound techniques for detection, diagnosis was being made
significantly earlier, with consequent apparent prolongation
of survival.
The liver is the major site of metabolism of Adriamycin
and approximately 40% of the drug is excreted via the biliary
tract (Riggs, 1977). Early studies (Benjamin et al., 1981) in
hyperbilirubinaemic patients with metastatic liver cancer
receiving intermittent bolus therapy demonstrated a delayed
clearance of Adriamycin. This formed a rational explanation
for the clinical observation that some of these patients
developed severe toxicity, particularly myelosuppression and
mucositis. It was on the basis of these observations that the
current dose reduction schedule in the presence of hyper-
bilirubinaemia has been applied to patients with secondary
liver cancer. There have, however, been some theoretical
reasons suggested why this may not necessarily apply to
patients with primary liver cancer. Thus Chleblowski et al.
(1981) have suggested that in the patient with HCC, the
tumour tissue may retain some effective drug-metabolising
capacity, whereas in metastatic liver disease the tumour
replaces functioning liver tissue. Similarly Chan et al. (1980),
on the basis of pharmacological studies showing little differ-
ence between HCC patients with disturbed liver tests and
other patients with normal liver function, have also suggested
that a 'more rigorous dose regimen' might be advantageous
in the treatment of HCC patients, despite some degree of
hepatic dysfunction.
Our data show that both views may be correct to varying
degrees. Thus the degree of leucopenia was inversely related
to the height of the serum bilirubin concentration and Figure 4
suggests that administration of the standard Adriamycin dose
(60 mg m2) to patients with bilirubin concentrations higher
than 40 iLmol 1-' would be most hazardous. Indeed, the white
cell count in the present patients may well have been lower
between days 7 and 14, and the degree of neutropenia greater
than indicated by the total white cell count. However, with
the exception of one patient who developed septicemia, the
patients tolerated the regimen and any associated myelo-
suppression well, and unlike the experience of Benjamin et al.
(1981), mucositis was uncommon. Whilst the relevance of
this clinically is limited by the lack of improvement in res-
ponse rate, the finding may still be valuable in respect of the
use of Adriamycin given by other approaches such as intra-
arterially, where is efficacy appears greater (Patt et al., 1987),
or in combination with other drugs.
Ballet et al. (1984) have reported a diminished hepatic
extraction of Adriamycin with values of less than 0.1 in five
HCC patients with cirrhosis and concluded that there is an
impairment of cellular transport in HCC patients even in the
absence of severe hepatic dysfunction. However these results
have been criticised (Kaye et al., 1985) on the grounds that
no distinction between Adriamycin and adriamycinol was
made and the timing of the sampling, and they are difficult to
reconcile with the normal values for clearance reported by
Chan et al. (1980) and referred to above. Much higher
extraction ratios were reported by Garnick et al. (1979) in
cancer patients with abnormal liver function tests, but these
patients did not have cirrhosis or HCC.
The extent to which toxicity is related to the phar-
macokinetics of Adriamycin remains controversial (Kaye et
al. (1985). Previous studies which have concentrated on com-
parison of pharmacokinetic parameters between patients with
normal and compromised liver function have suggested that
clearance of both Adriamycin and its metabolites was
delayed in patients with hyperbilirubinaemia (Benjamin et al.
(1981) but later work using HPLC techniques found little
difference in Adriamycin disposition though formation and
excretion of adriamycinol was invariably delayed (Chan et
al., 1980). Our data support the latter finding in that the
AUC for adriamycinol to 48 h was significantly greater in
those with hyperbilirubinaemia and the mean concentration-
time curve was also higher.
We could detect no relationship between the degree of
toxicity and any parameters including AUC and terminal
half-life, for either Adriamycin or adriamycinol. It is likely,
however, that the failure to detect any positive correlations is
a reflection of the small number of patients with complete
data and the narrow range of white cell nadirs seen in the
present patients irrespective of the serum bilirubin level (1.7
to 4.2x 109l-').
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Myers (1982) concluded that 'a convincing quantitative
relationship between liver function abnormalities and
impaired Adriamycin clearance has not been established'.
However, the present study strongly suggests that 'liver func-
tion', at least as reflected by the serum bilirubin concen-
tration, does indeed influence Adriamycin clearance. Our
results imply that this is reflected in increased toxicity; direct
statistical confirmation of this contention would almost cer-
tainly require very large numbers of patients.
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